Exelixis, Inc. (NASDAQ:EXEL) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET

Company Participants

Susan Hubbard - EVP of Public Affairs and IR

Mike Morrissey - President and CEO

Chris Senner - CFO

P.J. Haley - EVP of Commercial

Vicki Goodman - Chief Medical Officer

Peter Lamb - Chief Scientific Officer

Conference Call Participants

Asthika Goonewardene - Truist

Michael Schmidt - Guggenheim

Andy Hsieh - William Blair

Yaron Werber - Cowen

Jay Olson - Oppenheimer

Akash Tewari - Jefferies

Peter Lawson - Barclays

Chris Shibutani - Goldman Sachs

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Exelixis Q1 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that conference is being recorded.

I would now like to hand the conference over to your speaker, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please go ahead.

Susan Hubbard

Thank you, Shari, and thank you all for joining us for the Exelixis first quarter 2022 financial results conference call.

Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Vicki Goodman, our Chief Medical Officer; and Peter Lamb, our Chief Scientific Officer, who will together review our progress for the first quarter 2022 ended March 31, 2022.

During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website for an explanation of our reasons for using such non-GAAP measures as well as tables deriving these measures from our GAAP results.

During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners and the level of cost associated with discovery, product development, business development and commercialization activities.